Germany-based Bayer AG (ETR: BAYN) has announced that Chinese companies Epigenic Therapeutics, Shanghai Immunocan Biotech Co., Ltd., and AccurEdit Therapeutics will be housed at its Bayer Co.Lab Shanghai. This move aims to leverage Bayer’s global innovation and cooperation network, connecting global pharmaceutical industry resources to boost cell and gene therapy (CGT) innovation.
Bayer Co.Lab Shanghai: A Hub for Life Sciences Incubation
Bayer Co.Lab Shanghai, a life sciences incubator inaugurated in September 2024, is part of Bayer’s global network of incubators. This strategic expansion includes locations in Cambridge (US), Kobe (Japan), and Berlin (Germany), with the Shanghai facility officially opened last month. The incubator serves as a hub for fostering innovation in the life sciences sector, particularly in the burgeoning field of cell and gene therapy.
Boosting Cell and Gene Therapy Innovation
By housing these Chinese biotech firms, Bayer Co.Lab Shanghai is poised to accelerate the development of cutting-edge therapies and technologies in CGT. This collaboration will not only enhance the innovation capabilities of the companies involved but also contribute to the global advancement of medical treatments and healthcare solutions.-Fineline Info & Tech
